Sign In
Buy PRAX
$278.93
+20.85 (+8.08%)
At Close: Jun 03, 2026
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 02'nd Jun 2026
BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, to
Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint
06:09am, Tuesday, 02'nd Jun 2026
Praxis Precision Medicines Inc. (NASDAQ:PRAX) on Monday reported results from its Phase 2/3 POWER1 study of vormatrigine for focal onset seizures.
Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study
06:11pm, Monday, 01'st Jun 2026
Praxis Precision Medicines said on Monday its experimental epilepsy drug failed to meet the main goal of a mid- to late-stage study, prompting it to pause enrollment in another ongoing study whi
Praxis Precision Medicines Provides Vormatrigine Program Update
04:15pm, Monday, 01'st Jun 2026
POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second
Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
09:30pm, Tuesday, 12'th May 2026
Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript
01:21pm, Saturday, 09'th May 2026
Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript
Praxis Precision Medicines Q1 Earnings Call Highlights
04:15pm, Friday, 08'th May 2026
Praxis Precision Medicines NASDAQ: PRAX said it is preparing for two potential U.S. product launches while advancing several late-stage clinical programs, as management outlined first-quarter 2026 res
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
08:00am, Thursday, 07'th May 2026
FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 05'th May 2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, tod
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, tod
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of “Buy” by Brokerages
02:31am, Friday, 24'th Apr 2026
Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have been assigned an average rating of "Buy" from the twenty analysts that are currently covering the company, MarketBeat r
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
07:30am, Tuesday, 14'th Apr 2026
FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully in
Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential
04:10pm, Monday, 06'th Apr 2026
Praxis Precision Medicines, Inc. remains a Strong Buy, driven by two NDA submissions and pipeline expansion opportunities targeting essential tremor and developmental and epileptic encephalopathies. T
Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In Trial
09:08am, Monday, 06'th Apr 2026
Praxis said elsunersen demonstrated a placebo-adjusted seizure reduction from baseline of 77% (p=0.015) in pediatric patients with SCN2A developmental and epileptic encephalopathy.
Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observe
